Background Insulin-like growth factors (IGFs) are anabolic proteins that are essential regulators of cell division, differentiation and growth. We describe the longitudinal changes in IGF-I, IGF-II and the binding proteins IGFBP-1, -2 and -3 before and during normal pregnancy.
Introduction
Interest into the role of insulin-like growth factors (IGFs) has developed because of their diverse actions in the control of metabolic function and cell growth and di¡erentiation. IGFs are present in relatively high concentrations (nmol/L) in serum, and although they can be synthesized by nearly every mammalian cell, the liver is the predominant site of synthesis. The IGF axis consists of the IGFs (I and II), their binding proteins (IGFBPs 1^6), receptors (I and II) and the IGFBP proteases [e.g. prostate-speci¢c antigen (PSA)].
Both IGF-I and IGF-II are mitogenic substances with similarity to insulin, both structurally and function-ally. They are active anabolic hormones that function to increase glucose uptake, decrease protein and fat catabolism and cause long-term increases in linear growth, cell di¡erentiation and muscle mass.
The IGFBPs act as blood-to-tissue transporters and modulate the actions of IGFs by altering the free: bound ratio. In some circumstances, IGFBPs can have a direct IGF-independent action. 1 In this paper, we examine the changes that occur in three IGFBPs, namely IGFBP-1, IGFBP-2 and IGFBP-3. IGFBP-1 is important in ovum implantation and trophoblast invasion. 2 At high concentration, IGFBP-1 is generally inhibitory but can potentiate IGFs function at lower concentrations. 3 IGFBP-1 concentrations are inversely regulated by insulin. 3, 4 Similarly to IGFBP-2 and IGFBP-4, IGFBP-1 is small enough 3 to transport IGFs into extravascular compartments. IGFBP-2 is the second most abundant IGFBP in the circulation and is also considered to be inhibitory to the actions of IGFs, particularly to IGF-II. The most abundant IGFBP in adults is IGFBP-3, which is modulated by a number of factors including age, growth hormone (GH) and nutritional status. 5 IGFBP-3 has been shown to enhance the actions of IGFs 1 by protecting them from protease degradation. A number of IGFBP proteases modulate the free:bound IGF ratio and some have been identi¢ed in pregnancy serum. 1 The biological actions of IGFBPs are further complicated as alterations in their a¤nity for IGFs occur as a result of IGFBP phosphorylation or glycosylation. The numerous complex roles of IGFs and their binding proteins have been previously reviewed by Jones and Clemmens 3 and Rosen. 5 Previous research has demonstrated abnormalities in the maternal serum concentrations of IGFs and IGFBPs in clinical disease states such as preeclampsia, 6,7 gestational diabetes 8 and intra-uterine growth retardation, 9^11 compared with normal gestation. However, there are limited data on the normal sequential changes that occur in the IGF-axis components during normal pregnancy because many studies have investigated only one or both of the IGFs. This study investigates the changes of both IGFs and three IGFBPs, from pre-conception and throughout 41 uncomplicated pregnancies. These data can then be used in further studies to investigate the role of the IGF axis during the alterations in maternal metabolism that occur during pregnancy, such as bone remodelling and disease states associated with pregnancy.
In pregnancy, haemodilution has been shown to a¡ect many common analytes 12 and is considered to be an important physiological adaptation that bene¢ts the fetus. 13 This important response to metabolic changes has not been considered elsewhere. Possible decreases in the concentration of analytes in pregnancy might be shown to be caused by haemodilutional e¡ects. Conversely, possible increases in the concentration of analytes may be masked, unless haemodilutional e¡ects are taken into account. We have therefore presented our results with and without adjustment for albumin concentration, with explanations (if signi¢cantly di¡erent) and possible mechanisms for each scenario to allow the reader personally to interpret the data.
Subjects and methods

Subjects and design of the study
One hundred and forty-one healthy women attending the family planning clinic were recruited into the study. Of these women, 41 completed the study and ful¢lled the criteria, by becoming pregnant, provided a complete set of serum samples and had a normal delivery at term. All subjects gave informed consent to participate in the study, which was approved by the Nottingham City Hospital Ethics Committee. Clinical demographics for the women are shown in Table 1 .
Analytical methods
Serum samples were collected before conception, and then at 12, 24 and 36 weeks of pregnancy. Samples were collected between10 a.m. and 4 p.m. All samples were stored at 7708C prior to analysis and thawed immediately before assay. Samples from each subject were measured in a single batch. Single sample measurements were made when automated methods for measuring albumin and IGF-I concentrations were used, and in duplicate when manual assays were used to measure concentrations of IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3.
Assays for IGF-I, IGF-II and IGFBP1, IGFBP-2 and IGFBP-3 were carried out at the Supra-Regional Assay Centre, Guildford, Surrey, UK.
IGF-I was measured using a Nichols Advantage Immunoassay Analyser (Nichols Institute Diagnostics, San Clemente CA, USA). Inter-and intra-assay coe¤cients of variation (CVs) were 5.7% at 27.0 nmol/ L (nˆ20) and 5.2% at 30.0 nmol/ L (nˆ20), respectively. The limit of detection was 0.78 nmol/ L. IGF-II concentrations were measured using an inhouse radioimmunoas say (RIA) method. 14 Inter-and intra-assay coe¤cients of variation (CVs) at 20 nmol/ L were 11.8% (nˆ20) and 4.8% (nˆ10), respectively. The limit of detection was 11 nmol/ L; cross-reactivity with IGF-I was 3.7%. 15 An enzyme-linked immunosorbent assay (ELISA; Oy Medix Biochemica AB, Asematie, Finland) was used to quantify IGFBP-1. This assay detects the non-phosphorylated and slightly phosphorylated isoforms of IGFBP-1 but not the highly phosphorylated isoform. Inter-and intra-assay CVs were 7.4% and 3.4% at concentrations of 0.021 mg/L (nˆ15) and 0.022 mg/L (nˆ16), respectively, and the limit of detection was 0.0004 mg/L. IGFBP-2 was measured using an in-house RIA method, 16, 17 with inter-and intra-assay CVs of 18% (nˆ20) and 7% (nˆ10), respectively, at a concentration of 1.00 mg/L with a limit of detection of 0.03 mg/L. Total IGFBP-3 concentrations were measured using a Nichols Institute Diagnostics RIA 100T Kit (San Juan Capistrano CA, USA). Inter-and intra-assay CVs were 6.3% and 3.4% at concentrations of 1.69 mg/L and 1.72 mg/L (nˆ40), respectively, with a limit of detection of 0.06 mg/L (nˆ20). This assay detects intact IGFBP-3; it might also cross-react with proteolysed fragments.
Albumin measurement was carried out using a bromocresol purple method (Olympus Diagnostic Systems, Southall, UK) on an Olympus AU600 Analyser (Olympus Diagnostic Systems, Southall, UK).
Adjusted values were calculated using the following formula :
Measured concentration of growth factor or binding protein £ Preconceptual albumin concentration Albumin concentration at time t
The initial values produced and the adjusted values are shown in Figs 1^5.We adjusted values for changes in albumin concentrations to allow for any possible dilutional e¡ects of pregnancy. However, there is considerable disagreement over the validity of adjusting values for changes in £uid balance during pregnancy which has not yet been proven. We have only commented on the adjusted and unadjusted values if there was a signi¢cant di¡erence between both sets of results.
Statistical analysis
IGF-I, IGF-II and the binding proteins IGFBP-1, -2 and -3 are expressed as mean absolute changes before and after adjustment for haemodilution changes. The means of each group were not always parametrically distributed and therefore statistical di¡erences were assessed using the Wilcoxon signed rank test. Statistical analysis was carried out using Analyse-It statistical software (Analyse-It, Leeds, UK). A P value of 50.05 was deemed signi¢cant at 95% con¢dence interval.
Results
The absolute changes in IGFand IGFBP concentrations are shown in Figs 1^5, with corresponding albumin concentrations shown in Table 1 . Adjusting for haemodilution had little e¡ect on the overall trend and only increased the signi¢cant change in IGF-I concentration in the third trimester (see Fig. 1 ). This changing pattern in IGF-I concentration is similar to that previously published by Black et al. 18 and Naylor et al. 19 During pregnancy, there was little change in IGF-II concentration compared with pre-conception values, similar to the ¢ndings of previous studies. 20^22 However, adjusting for haemodilution suggested that IGF-II concentration may actually increase during pregnancy, producing a response similar to that of IGF-I (see Fig. 2 ). Before conception, the average IGFBP-1 concentration was close to the limit of detection. There was little di¡erence after adjustment for albumin^both sets of data showed a dramatic increase over gestation. At each gestational time point, serum IGFBP-1 concentrations were signi¢cantly increased compared with pre-conceptual concentrations (P50.0001; see Fig. 3 ). Like IGF-II, adjusted values showed a signi¢cant change in the overall trend in IGFBP-2 concentrations during pregnancy (see Fig. 4 ). Concentrations of IGFBP-3 in the maternal serum increased steadily throughout pregnancy, similar changes were previously reported by Wang et al. 22 The overall trend during gestation was not a¡ected by albumin adjustment; however, adjustment increased the signi¢cance of the changes seen for IGF-I.
Discussion
IGFs, through the action of GH, 23 may play important roles in bone metabolism during gestation. 18 Possible biochemical modulators of bone turnover, such as parathyroid hormone (PTH), parathyroid hormonerelated peptide, interleukins and IGFs 18, 24 have been investigated, and the main regulator of bone metabolism is still unknown. 25 This study was undertaken to investigate whether serum IGFs and IGFBPs play a role in calcium homeostasis throughout pregnancy. To our knowledge, no other studies with this cohort of patients have investigated the changes in IGF-I, IGF-II and their binding proteins during pregnancy.
Pregnancy is a complicated metabolic state in which the role of the placenta is to alter the mother's metabolism to allow a su¤cient supply of nutrients for adequate fetal growth. On the maternal side of the placenta, GH enhances IGF-I and IGFBP-3 production to bring about a state of insulin resistance. On the fetal side, IGF-II, IGFBP-1 and IGFBP-2 regulate cell development and growth by paracrine and autocrine mechanisms.
The increase in maternal IGF-I concentrations seen in our study has also been observed in other serial data studies. 7, 18, 19, 26 To our knowledge, only Black et al. 18 and Naylor et al. 19 have published data from preconception to the third trimester. Patient numbers were smaller than this study, but the changes in IGF-I concentrations throughout gestation found in both studies are further con¢rmed by our data. Placental GH is detectable in the maternal serum at 14 weeks of gestation and increases signi¢cantly at 28 weeks. 23 Its action suppresses the release of maternal pituitary GH, but it is also a stimulator of IGF-I production, 27 which is signi¢cantly correlated over gestation. 28 In a rat model, 29 the fall in IGF-I during early pregnancy is followed by a rise from the second trimester onwards and has been attributed to nutrient storage in early pregnancy, ready for the catabolic changes caused by increasing fetal demands during the later period of pregnancy. 29 Ann Clin Biochem 2004; 41: 220-226 In contrast to the amount of published information on IGF-I in pregnancy, there is little knowledge of the physiological roles of IGF-II during gestation. 8, 30 Current literature emphasizes the importance of IGF-II for embryonic, placental and fetal development. 30^32 De¢ciency in placenta-derived IGF-II produces growth retardation in mice, which is linked to nutritional transportation. 31 Its importance as a fetal growth regulator is attributed to the fact that IGF-II is present in much higher concentrations than IGF-I 33 in fetal serum and increases signi¢cantly after 20 weeks of gestation. 32 The absolute changes in IGF-II in the maternal circulation indicate an overall fall after pregnancy. However, after taking the e¡ect of haemodilution into account, the fall is only signi¢cantly di¡erent at 12 weeks compared with pre-conception values and follows a large increase towards the third trimester. The mRNA of IGF-II is abundantly expressed in the trophoblasts of maternal vessels throughout pregnancy. 34 However, cross-sectional data 20, 21 and the absolute changes in this study have not shown any signi¢cant increases over gestation unless the e¡ect of haemodilution is taken into account. The method used in this study detects all molecular-weight forms of IGF-II in serum. 17 It is feasible to expect that the total IGF-II would increase throughout pregnancy because its production by the placenta directly controls the supply of maternal nutrients to the fetus. 31 This observation is only made when haemodilution is taken into account.
IGF-II has been shown to also stimulate IGFBP-1 synthesis. 34 IGFBP-1 is produced by the decidualized endometrial cells during pregnancy, 35 accounting for the rapid increase in this binding protein in the ¢rst trimester. It is suggested that IGFBP-1 is important for successful trophoblast implantation and to promote cell proliferation, and may play a role in intra-uterine growth retardation 36 and pre-eclampsia. 9 IGFBP-1 responds rapidly to changes in IGF-I and therefore is a¡ected in non-fasted sampling. 37 It also shows diurnal variation, 30 and this may account for di¡erences seen in the literature. The fasting status of pregnant women during this study proved di¤cult and therefore prandial and diurnal variation could have contributed to an increase in the production of IGFBP-1. However, the rapid increase in this binding protein over gestation was signi¢cant in all women throughout gestation, which has also been shown in other cross-sectional and serial studies of non-pregnant and pregnant women. 9, 37, 38 All these studies showed that total IGFBP-1 peaked at 12 weeks. One study showed a plateau until term, 38 whilst others showed a decline by 24 weeks. 9, 37 Concentrations of IGFBP-1, 39 like IGFBP-3, 10 are reported to be higher in twin or multiple pregnancies. However, interestingly, the maternal serum IGF-I concentration in one twin pregnancy in this study was one of the lowest of the group.
As with IGF-II, there are little published data regarding changes in IGFBP-2 throughout gestation. IGFBP-2 has been shown to be inhibitory to the actions of both IGFs, especially IGF-II. 3 It is found in much higher concentrations in the fetal circulation, suggesting a vital role in augmenting the fetal response to IGF-I and, particularly, IGF-II. 3 The fall in maternal IGFBP-2 concentrations from pre-conception to 12 weeks of gestation shown in our study has also been reported by Chard et al. 40 Adjusting IGFBP-2 concentrations for haemodilution in the same manner as for IGF-II has a profound e¡ect on the changes during pregnancy. Absolute values show a signi¢cant fall in IGFBP-2 from conception until the second trimester, followed by a small increase that does not return to pre-conception values at any point. A previous study of IGFBP-2 measured between 24 and 42 weeks reported no di¡erence in a pregnant population compared with a non-pregnant group, 41 but this is not con¢rmed by our data. Only by adjusting for haemodilution is there no statistical di¡erence between 24 and 36 weeks compared with preconception. Di¡erences between studies could be the result of di¡ering methodologies, particularly antibody cross-reaction with IGFBP-2 fragments. 42 Roberts et al. 43 have put forward a hypothesis to explain this di¡erence: maternal circulating IGF-II promotes placental structural development in early pregnancy, while in later pregnancy increased binding to IGFBP-2 inhibits the progression of placental growth and development. It is possible, therefore, that increases in IGF-II in late pregnancy result in the increased production of IGFBP-2 to prevent an uncontrolled increase in placental mass. Alternatively, an increase in IGFBP-2 protease activity, resulting in increased concentrations of IGFBP-2 fragments, might have contaminated the in-house assay. 42 The increasing concentration of IGFBP-3 in maternal serum during gestation observed in our study has also been seen in many other studies 10, 22, 41, 44 but it was not con¢rmed by all. 33 Like IGF-I, IGFBP-3 is controlled by GH, nutrition, age, exercise and IGF-I itself. 30 IGFBP-3 is a major binding protein that signi¢cantly increases the half-life of circulating IGFs. Free IGF-I is increased in pregnancy compared with total IGF-I and this is thought to occur via increased IGFBP-3 protease activity. 45 The action of IGFBP-3 proteases produces di¡erent IGFBP-3 fragments, and it has been shown that measurement of total IGFBP-3 by RIA or immunoradiometric assay cannot distinguish between intact and proteolysed forms. 10 This might indicate that while we detected an increased production of total IGFBP-3 throughout gestation, it may also be due to increased IGFBP-3 fragments. The suppliers of the IGFBP-3 kit did not have any information on the cross-reactivity of intact IGFBP-3 with its fragments but did state that the assay we used is likely to detect some of these fragments (J Wilde, personal communication). 46 This may indicate that while we detected increased production of total IGFBP-3 throughout gestation, it may also have been caused by increased concentrations of IGFBP-3 fragments.
Conclusion
This work consolidates and supports observations from several other publications on the changes in IGFs and their binding proteins before and during pregnancy.
